We have entered into a capital and business alliance with J-ARM, a company that provides Regenerative medicine support services for animals. This
alliance aims to support the health of companion animals through a Regenerative medicine approach.
January 26, 2023
ROHTO Pharmaceutical Co., Ltd. (Headquarters: Osaka City, President: Masafumi Sugimoto) is pleased to announce that, in order to realize an even more well-being society, it has entered into a capital Companion Animal Business with Regenerative medicine-ARM Co., Ltd. (Headquarters: Osaka City, Representative: Yukio Takene, hereinafter "J-ARM"), a provider of regenerative medicine support services for animals, effective January 26th. This alliance aims to establish regenerative treatment methods for diseases that are difficult to treat with existing technologies, and to contribute to veterinary medicine with Rohto's Regenerative medicine technology. This business will cover a wide range of areas, from "preventive medicine (self-care)" that is close to daily life to "treatment (professional care)" through Regenerative medicine, and will support the health of animals throughout their life stages, from prevention and pre-disease to treatment, just as Rohto aims for with humans.
*CA stands for Companion Animal. It refers to a pet or companion animal.
Background and purpose of the investment
Our company, under ROHTO Group Comprehensive Management Vision 2030, "Connect for Well-being," is expanding into Regenerative medicine and food businesses, and is undertaking various initiatives with the aim of realizing a well-being society. Recognizing that CAs (Cardiac Animals) are irreplaceable to human beings, we believe that the happiness of CAs is not limited to CAs themselves but also contributes to the well-being of all people. Based on this belief, we have applied the research capabilities and networks we have cultivated to launch a new business in November 2022 to support the health of CAs.
In the field of CA treatment, just as in humans, there are still many diseases that are difficult to treat with current technology, such as neurological and spinal cord diseases, heart diseases, liver diseases, kidney diseases, and autoimmune diseases. By combining our Regenerative medicine technology with J-ARM's efforts in animal Regenerative medicine, we expect to be able to solve challenges such as developing effective treatments for these diseases.
Details of the partnership
J-ARM is developing a business supporting the introduction of cell therapy and Regenerative medicine for animal hospitals and has a strong track record in the veterinary field. By combining their expertise with our Regenerative medicine technologies, such as high-quality and stable cell culture technology and serum-free culture medium development, which we have cultivated in the human field, we will begin our collaboration by specifically engaging in cell culture kit business, cell culture analysis services, and the provision of serum-free culture media.
Regarding capital investment, we plan to invest by acquiring newly issued shares from J-ARM. The impact of this matter on our consolidated financial results for the fiscal year ending March 2023 is expected to be minor, and we will promptly inform you of any further matters that need to be disclosed.
About J-ARM
| Company Name |
J-ARM Co., Ltd. |
| representative |
Yukio Takene |
| location |
La Luce Abeno 201, 5-9-27 Abenosuji, Abeno-ku, Osaka City, Osaka Prefecture |
| Establishment |
April 2006 |
| URL |
http://j-arm.biz/ |
| Business details |
Support for the introduction of cell therapy and Regenerative medicine, and research and development of culture media and culture technology (cell culture). |